0000000000017878

AUTHOR

Marco Giunta

showing 14 related works from this author

Delayed-Onset Superior Mesenteric Artery Syndrome Presenting as Oesophageal Peptic Stricture

2012

Superior mesenteric artery (SMA) syndrome is an infrequent cause of vomiting and weight loss due to compression of the third part of the duodenum by the SMA. We describe the case of a 17-year-old woman, admitted to our department for progressive dysphagia and severe weight loss due to an oesophageal peptic stricture, caused by chronic acid reflux secondary to duodenal compression by the SMA. Symptoms improved after (par)enteral nutrition and repeated oesophageal dilatation, thus supporting the role of intensive medical and endoscopic intervention as an alternative to surgery, at least in some cases.

medicine.medical_specialtySettore MED/09 - Medicina InternaPepticGastroenterologymedicine.arteryInternal medicinemedicineOesophageal dilatationSuperior mesenteric arterySuperior mesenteric artery syndromelcsh:RC799-869Settore MED/12 - Gastroenterologiabusiness.industryGastroenterologymedicine.diseaseSMA*DysphagiaParenteral nutritionmedicine.anatomical_structureVomitingDuodenumlcsh:Diseases of the digestive system. Gastroenterologymedicine.symptomPublished online: March 2012businessSuperior mesenteric artery syndromeChronic acid refluxCase Reports in Gastroenterology
researchProduct

Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials.

1999

The purpose of this study was to evaluate the clinical usefulness of surrogate markers of the interferon effect (i.e., alanine aminotransferase levels and serum HCV-RNA status) as predictors of long term response, and to identify the optimal schedule of treatment for patients with chronic hepatitis C by means of meta-analysis.Pertinent randomized clinical trials and prospective studies were selected using MEDLINE (1986-1996), a reference list from published articles or reviews. Twenty-six prospective studies reporting data on surrogate markers of interferon response were selected. Thirty-nine trials comparing interferon alpha to no treatment and 25 trials comparing different schedules of in…

medicine.medical_specialtymedicine.medical_treatmentHepatitis C virusHepacivirusAlpha interferonHepacivirusmedicine.disease_causeGastroenterologyDrug Administration Schedulelaw.inventionFlaviviridaeChronic hepatitisRandomized controlled triallawInternal medicinemedicineHumansInterferon alfaRandomized Controlled Trials as TopicHepatologybiologybusiness.industryGastroenterologyInterferon-alphaAlanine TransaminaseImmunotherapyHepatitis C Chronicbiology.organism_classificationImmunologyRNA Viralbusinessmedicine.drugThe American journal of gastroenterology
researchProduct

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.

2001

Abstract Background/Aims : To evaluate by meta-analysis of available literature whether interferon (IFN) reduces the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV)-related Child A cirrhosis. Methods : Three randomized controlled trials and 15 nonrandomized controlled trials, including 4614 patients and comparing IFN to no treatment, were selected. Data on the incidence of HCC in IFN treated and untreated patients were extracted from each study. Meta-analysis by the DerSimonian and Laird risk difference (RD) method was used to pool observations. Results : A different incidence of HCC between treated and untreated cirrhotic pati…

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatocellular carcinoma; Interferon; Viral cirrhosis;Hepatitis C virusmedicine.disease_causeGastroenterologyAntiviral AgentsInternal medicinemedicineCarcinomaHumansHepatitis B virusClinical Trials as TopicHepatologybusiness.industryIncidence (epidemiology)Liver Neoplasmsmedicine.diseaseHepatitis Cdigestive system diseasesHepatocellular carcinomaImmunologyViral diseaseInterferonsbusinessViral hepatitisJournal of hepatology
researchProduct

The long-term course of chronic hepatitis B

1999

The aim of this study was to assess the long-term outcome in hepatitis B virus (HBV)-infected patients according to HBV, hepatitis C virus (HCV), and hepatitis D virus (HDV) replication, focusing on survival, liver failure, and hepatocellular carcinoma (HCC). A cohort of 302 hepatitis B surface antigen (HBsAg)-positive subjects (mean age, 34 +/- 15.3 years; male/female 214/88; 39 subjects under 14 years) with biopsy-proven chronic hepatitis (86 with cirrhosis) was prospectively assessed, with a median follow-up of 94 +/- 37.6 months. One hundred nine patients received interferon alfa (IFN). At baseline, 86 subjects (28.5%) were hepatitis B e antigen (HBeAg)-positive (wild-type HBV), 80 (26.…

Hepatitis B virusmedicine.medical_specialtyHBsAgCirrhosisHepatologybusiness.industryHepatitis C virusvirus diseasesHepatitis Bmedicine.disease_causemedicine.diseaseGastroenterologydigestive system diseasesSurgeryHBeAgInternal medicineHepatocellular carcinomamedicineHepatitis D virusbusinessHepatology
researchProduct

ADVANCED ENDOSCOPIC IMAGING FOR SURVEILLANCE FOR DYSPLASIA AND COLORECTAL CANCER IN INFLAMMATORY BOWEL DISEASE: COULD THE PATHOLOGIST BE FURTHER HELP…

2014

Patients with inflammatory bowel disease (IBD) have an increased risk of developing intestinal cancer. The magnitude of that increased risk as well as how best to mitigate it remain a topic of ongoing investigation in the field. It is important to quantify the risk of colorectal cancer in association with IBD. The reported risk varies widely between studies. This is partly due to the different methodologies used in the studies. Because of the limitations of surveillance strategies based on the detection of dysplasia, advanced endoscopic imaging and techniques involving the detection of alterations in mucosal antigens and genetic abnormalities are being investigated. Development of new bioma…

Pathologymedicine.medical_specialtyColorectal cancerReview ArticleComorbidityInflammatory bowel diseaseEndoscopy GastrointestinalADVANCED ENDOSCOPIC IMAGING DYSPLASSIA COLON CANCER IBDEndoscopic imagingRisk Factorsinflammatory bowel diseasemedicineHumanslcsh:RC799-869Intestinal Cancerulcerative colitisPatient Care TeamCrohn's diseaseSettore MED/12 - GastroenterologiaMicroscopy Confocalbusiness.industryCrohn′s diseaseGastroenterologyInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisColorectal cancerdigestive system diseasesCrohn's diseaseSettore MED/18 - Chirurgia GeneraleDysplasiaPopulation SurveillancesurveillanceBiomarker (medicine)lcsh:Diseases of the digestive system. GastroenterologyColorectal Neoplasmsbusiness
researchProduct

Efficacy of pneumatic dilatation for the treatment of idiopatic achalasia: a single-center experience

2015

Pneumatic dilatation (PD) and Surgical Miotomy (SM) are presently the best treatments for untreated achalasia, with similar efficacy. There is no information on the relative efficacy of PD in younger compared to older patients. Aim of our study was to compare success rate and safety of PD in patients under fifty years old and in those over fifty years old affected by achalasia. Twenty consecutive symptomatic patients were treated in our Unit with graded PD under fluoroscopic view. Five male and 15 female with a median age of 47 years were treated. Twelve patients were less than fifty years old (group I) while 8 were older (group II). Median dysphagia questionnaire score was 14 and13 ingroup…

MarketingPharmacologySettore MED/12 - GastroenterologiaOrganizational Behavior and Human Resource Managementmedicine.medical_specialtyRelative efficacybusiness.industryStrategy and ManagementGroup iiComplete remissionPharmaceutical ScienceAchalasiamedicine.diseaseSingle CenterDysphagiaSurgerySettore MED/18 - Chirurgia Generaleachalasia pneumatic dilatation esophageal obstructionOlder patientsDrug DiscoverymedicineIn patientmedicine.symptombusinessAbdomen
researchProduct

Long-term course of interferon-treated chronic hepatitis C

1998

Abstract Background/Aims: To evaluate whether sustained response to α-interferon improves clinical outcome in patients with chronic hepatitis C. Methods: A cohort of 410 consecutive patients (65% with chronic hepatitis, 35% with cirrhosis) were treated with α-interferon in two trials (mean follow-up 62.1 months, range 7–109 months). All were serum HCV RNA positive before therapy and received first 10 then 5 million units of α-2b or α-n1 interferon three times weekly for 6 to 12 months. Sustained response was defined as normal aminotransferases 12 months after stopping interferon. Results: Sixty-two patients (15.1%: 54 with chronic hepatitis, eight with cirrhosis) were sustained responders. …

AdultMalemedicine.medical_specialtyTime FactorsCirrhosisHepacivirusHepatitis C virusStatistics as TopicAlpha interferonmedicine.disease_causeAntiviral AgentsGastroenterologyLiver diseaseInternal medicineAscitesmedicineHumansInterferon alfaHepatologybiologybusiness.industryInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseTreatment OutcomeImmunologyFemalemedicine.symptombusinessFollow-Up Studiesmedicine.drugJournal of Hepatology
researchProduct

A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C

1997

In chronic hepatitis C virus (HCV) infection, the rate of sustained response to interferon is low. We evaluated, in patients responding to a 26-week course of interferon, the effect of high-dose maintenance therapy in preventing relapse. Three hundred and ten patients with chronic HCV infection (38.3% with cirrhosis, 80.6% with HCV type 1) received interferon alfa-2b for 26 weeks (10 MU tiw for 8 weeks, then 5 MU tiw for 18 weeks). One hundred and twenty-four subjects (40%) normalized aminotransferases, and were allocated randomly either to continue on 5 MU tiw for a further 26 weeks (prolonged therapy group: 60 patients) or to stop interferon (brief therapy group: 64 patients). Fifty-two w…

education.field_of_studyChemotherapyCirrhosisbusiness.industryHepatitis C virusmedicine.medical_treatmentPopulationAlpha interferonmedicine.disease_causemedicine.diseaseVirologyInfectious DiseasesMaintenance therapyVirologymedicineAdverse effectbusinesseducationInterferon alfamedicine.drugJournal of Medical Virology
researchProduct

Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study.

2016

Abstract Background Adalimumab is effective in the treatment of Crohn's disease. We have already reported data on the efficacy of adalimumab in 110 steroid-dependent patients. At the end of the study 90 patients (64.5%) maintained clinical remission. Aims To assess efficacy and safety of adalimumab after 6 years in patients of the original cohort who responded to treatment. Methods The present study is an extension of the published paper on 90/110 patients. We report results on clinical remission and safety of 6 year maintenance therapy with adalimumab. Results Of the original cohort 90 patients completed the study, 17 were lost to follow-up and 3 died. At the end of follow-up (74.16 ± 10.3…

0301 basic medicineMaleAnti-Inflammatory AgentsKaplan-Meier EstimateSingle CenterInflammatory bowel diseaseInflammatory bowel disease0302 clinical medicineMaintenance therapyCrohn DiseaseLong term therapyProspective Studiesskin and connective tissue diseasesProspective cohort studyMultivariate AnalysiCrohn's diseaseRemission InductionGastroenterologyMiddle AgedCrohn's diseaseAnti-Inflammatory AgentTreatment OutcomeItalyCohort030211 gastroenterology & hepatologyFemaleSteroidsHumanmedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtySteroid dependencyMaintenance Chemotherapy03 medical and health sciencesInternal medicinemedicineAdalimumabHumansAdverse effectSteroidHepatologybusiness.industryAdalimumabmedicine.diseaseSurgeryProspective Studie030104 developmental biologyMultivariate AnalysisbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis.

1997

Several randomized clinical trials of interferon in chronic hepatitis C have examined the histological changes in paired biopsy specimens. We have attempted a quantitative evaluation by meta-analysis.Randomized Clinical Trials found by MEDLINE search were included if: a) they compared different IFN regimens with non-active treatment or with each other, b) they obtained biopsies before starting and at the time of stopping IFN in a sizable proportion of the treated and control patients, and c) they assessed the biopsy-specimens semi-quantitatively according to Scheuer's numerical scoring system or Knodell's Histological Activity Index, with quantitation of fibrosis and of lobular, portal and …

Adultmedicine.medical_specialtyPathologyBiopsyMEDLINEGastroenterologylaw.inventionRandomized controlled trialLiver Function TestslawInterferonFibrosisInternal medicineBiopsyMedicineHumansRandomized Controlled Trials as TopicHepatologymedicine.diagnostic_testbusiness.industryHistologyAlanine Transaminasemedicine.diseaseHepatitis CLiverMeta-analysisHistopathologyInterferonsbusinessLiver function testsmedicine.drugJournal of hepatology
researchProduct

Could growth hormone play a role in Peutz Jeghers syndrome?

2013

Convincing experimental data suggest that the growth hormone (GH)/insulin-like growth factor-1(IGF-1) axis plays an important role in cancer development and behaviour. Epidemiological studies have supported an association with cancer, but not with tumour induction per se, although this is a distinction that is important mechanistically but not clinically [1]. We report the case of a 17-year-old man with delayed growth of pituitary origin, treated with growth hormone, in whom a diagnosis of Peutz-Jeghers syndrome (PJS) was subsequently made, and in whom, during the endoscopic follow-up, the number of polyps reduced dramatically, thus suggesting a role for GH in eliciting this disease.

business.industryDwarfismPeutz–Jeghers syndromeGeneral MedicineBioinformaticsmedicine.diseaseGrowth hormoneSettore MED/13 - EndocrinologiaSettore MED/03 - Genetica MedicaMutation (genetic algorithm)MedicinePeutz Jeghers syndromebusinessGrowth hormoneMedical Hypotheses
researchProduct

Chronic hepatitis C: Interferon retreatment of relapsers. A meta-analysis of individual patient data

1999

Relapse after interferon (IFN) therapy for chronic hepatitis C virus (HCV) infection occurs in 50% of patients after the initial response. The benefit of retreatment with IFN alone has not been assessed in large controlled studies. To assess the effectiveness and the tolerability of IFN retreatment and to identify the optimal second course regimen, we performed a meta-analysis of individual patient's data on a set of 549 patients (mean age 43.8 years; 12.2 SD, men: 65%) who had an end-of-treatment biochemical response to a first IFN course and then relapsed. Retreatment was started within 24 months after the end of the first course. Biochemical end-of-treatment responses (ETR) and sustained…

medicine.medical_specialtyCirrhosisMultivariate analysisHepatologybusiness.industryeducationmedicine.diseaseGastroenterologyhumanitiesConfidence intervalSurgeryRegimenTolerabilityInterferonMeta-analysisInternal medicinemedicineAdverse effectbusinessmedicine.drugHepatology
researchProduct

Clinical aspects of bleeding complications in cirrhotic patients

2000

Liver disease is a frequent cause of haemostatic abnormalities, which may lead to overt or occult bleeding. Clinical manifestations of hepatic coagulopathy include upper and lower gastrointestinal haemorrhage, easy bruising and bleeding from gums, nose or the female genital tract. The most significant bleeding problem among patients with chronic liver disease is blood loss due to portal hypertension. About 30% of subjects with oesophageal or gastric varices resulting from cirrhosis have an episode of gastrointestinal bleeding in their lifetime. Risk factors for the first episode of variceal bleeding include the severity of liver dysfunction, large varices, and the presence of endoscopic red…

Liver CirrhosisMaleGastrointestinal bleedingmedicine.medical_specialtyCirrhosisBiopsyDysfunctional uterine bleedingHemorrhageFactor VIIaChronic liver diseasePostoperative ComplicationsmedicineHumansFirst episodebusiness.industryBacterial InfectionsHematologyGeneral MedicineGastric varicesmedicine.diseaseRecombinant ProteinsSurgeryPortal hypertensionFemalemedicine.symptombusinessVaricesBlood Coagulation & Fibrinolysis
researchProduct

Definition of response to antiviral therapy in chronic hepatitis C

2000

ChemotherapyTime FactorsHepatologybusiness.industrymedicine.medical_treatmentRemission InductionFollow up studiesAntiviral therapyAlanine TransaminaseHepacivirusHepatitis C ChronicBiological effectResponse VariabilityAntiviral AgentsSensitivity and SpecificityImmune systemChronic hepatitisPredictive Value of TestsImmunologymedicineHumansRNA ViralViral diseasebusiness
researchProduct